News | Defibrillator Monitors | June 21, 2016

Zoll LifeVest Shows 97 Percent One-Year Survival for High-Risk Patients

Results from WEARIT-II registry show survival was also high for patients who experienced a clinically meaningful arrhythmia

Zoll LifeVest wearable defibrillator, WEARIT-II Registry results, CardioStim EuroPace 2016

June 21, 2016 — Zoll Medical Corp. announced that patients experience a high one-year survival rate following use of the LifeVest Wearable Defibrillator. New results from the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry) were presented by Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, during the Late-Breaking Clinical Trials session at CardioStim/EuroPace 2016.

The WEARIT-II prospective registry includes more than 2,000 patients prescribed the LifeVest Wearable Defibrillator with U.S. enrollment completed in 2015. One-year survival following use of the LifeVest across all patients was high at 97 percent. Notably, one-year survival for patients who experienced ventricular tachycardia (VT)/ventricular fibrillation (VF) during use of the LifeVest was also high at 92 percent. There was no difference in survival between patients with ischemic or non-ischemic cardiomyopathy.

Previously reported results from the WEARIT-II registry demonstrated a high sustained VT/VF event rate, with 22 events per 100 patient-years—2.1 percent of patients had a VT/VF event. One in 14 patients experienced a clinically meaningful arrhythmia requiring intervention while wearing the LifeVest.

Patients in the study used the LifeVest for a median of 90 days and only 40 percent received an implantable defibrillator following LifeVest use, according to Zoll LifeVest President Jason T. Whiting. He also noted survival was high even approximately nine months after ending use of LifeVest.

The wearable defibrillator is included in the 2015 European Society of Cardiology Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death and has received formal recommendations in the 2016 American Heart Association Science Advisory for the Wearable Cardioverter Defibrillator, with endorsement from the Heart Rhythm Society.

On any given day, tens of thousands of people around the world are protected from sudden cardiac death (SCD) by the LifeVest Wearable Defibrillator. The LifeVest is used for a wide range of patient conditions or situations, including following a myocardial infarction, before or after coronary revascularization, and for those with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.

The LifeVest is lightweight and easy to wear, allowing patients to return to their common activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

For more information: www.lifevest.zoll.com

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...